EMCDDA initial report on the new psychoactive substance 4F-MDMB-BICA

Methyl 2-({[1-(4-fluorobutyl)-1H-indol-3-yl]carbonyl}amino)-3,3-dimethylbutanoate (4F-MDMB-BICA) is a synthetic cannabinoid receptor agonist. Similar to other synthetic cannabinoids, it is sold as a ‘legal’ replacement for cannabis. Because of their high potency, synthetic cannabinoids can pose a high risk of severe poisoning, which in some cases can be fatal.

Based on potential public health risks, an initial report has been prepared and submitted to the Commission and the Member States, in accordance with Article 5b of Regulation (EC) No 1920/2006 (as amended). Its purpose is to provide scientific evidence to the Commission to allow it to make an informed decision regarding whether or not there is a need to request a risk assessment on a new psychoactive substance.